p53 protein expression in central nervous system neoplasms.

Area of Science:

• Neuro-oncology
• Molecular pathology
• Cancer genetics

Background:

• The p53 tumor suppressor gene plays a critical role in cell cycle regulation and apoptosis.
• Mutations in the p53 gene are common in various cancers, including central nervous system (CNS) tumors.
• Immunohistochemistry is a valuable tool for detecting protein expression and assessing cellular alterations in tumor tissues.

Purpose of the Study:

• To immunohistochemically evaluate p53 protein expression in a cohort of CNS tumors.
• To investigate the correlation between p53 protein expression and the proliferation marker PCNA (proliferating cell nuclear antigen).
• To assess the diagnostic and prognostic implications of p53 alterations in different CNS tumor types.

Main Methods:

• Immunohistochemical staining was performed on 86 surgically resected CNS tumor specimens.
• Monoclonal and polyclonal antibodies against p53 protein and a monoclonal antibody against PCNA were utilized.
• Normal brain tissue and gliotic brain parenchyma samples served as controls.

Main Results:

• p53 protein expression was identified in 35 out of 86 CNS tumors, suggesting frequent p53 gene mutations.
• p53 alterations were associated with astrocytic tumors of all grades, except pilocytic astrocytomas.
• In oligodendroglial and ependymal tumors, p53 alterations were predominantly observed in high-grade lesions.
• No p53 immunoreactivity was detected in normal or gliotic brain tissue.
• p53 altered expression did not correlate with the percentage of PCNA-labeled cells.

Conclusions:

• Immunohistochemical detection of p53 alterations can aid in distinguishing reactive from neoplastic astrocytic lesions.
• Sensitive immunohistochemical methods may help identify malignant progression in non-astrocytic glial tumors.
• CNS tumors with similar histological features may represent genetically heterogeneous groups with distinct clinical behaviors.